1	TITLE PAGE
2	
3	Identifying medications underlying communication
4	atypicalities in psychotic and affective disorders:
5	A pharmacovigilance study within the FDA Adverse Event
6	Reporting System
7	
8	Authors: Michele Fusaroli ¹ , Arndis Simonsen ²⁻³ , Stephanie A. Borrie ⁴ ,
9	Daniel M. Low ⁵⁻⁶ , Alberto Parola ⁷⁻⁸ , Emanuel Raschi ¹ , Elisabetta
10	Poluzzi ¹ , Riccardo Fusaroli ³⁻⁸⁻⁹
11	
12	Affiliations:
13	1 Department of Medical and Surgical Sciences (DIMEC), Pharmacology Unit, University of Bologna, 40126
14	Bologna, Italy.
15	2 Psychosis Research Unit - Department of Clinical Medicine, Aarhus University, Denmark
16	³ The Interacting Minds Center - School of Culture and Society, Aarhus University, Denmark
17	4 Department of Communicative Disorders and Deaf Education, Utah State University, Logan
18	5 Department of Brain and Cognitive Sciences, MIT, Cambridge, Massachusetts
19	⁶ Program in Speech and Hearing Bioscience and Technology, Harvard Medical School, Boston, Massachusetts

- 20 7 Department of Psychology, University of Turin, Turin, Italy
- 21 Bepartment of Linguistics, Cognitive Science and Semiotics, Aarhus University, 8000 Aarhus C, Denmark
- 22 9 Linguistic Data Consortium – University of Pennsylvania
- 23
- 24 Corresponding author: Michele Fusaroli, e-mail: michele.fusaroli2@unibo.it
- 25 ORCID:

26	Michele Fusaroli:	0000-0002-0254-2212
27	Arndis Simonsen:	0000-0002-5044-9936
28	Stephanie A. Borrie:	0000-0002-2336-0071
29	Daniel M. Low:	0000-0002-8866-8667
30	Emanuel Raschi:	0000-0003-0487-7996
31	Elisabetta Poluzzi:	0000-0002-7209-0426
32	Riccardo Fusaroli:	0000-0003-4775-5219

33 Abstract

34 **Purpose:** Communication atypicalities are considered promising markers of a broad 35 range of clinical conditions. However, little is known about the mechanisms and 36 confounders underlying them. Medications might have a crucial, relatively unknown 37 role both as potential confounders and offering an insight on the mechanisms at 38 work. The integration of regulatory documents with disproportionality analyses 39 provides a more comprehensive picture to account for in future investigations of 40 communication-related markers. The aim of the current study was to identify a list of 41 drugs potentially associated with communicative atypicalities within psychotic and 42 affective disorders.

43 Method: We developed a query using the Medical Dictionary for Regulatory 44 Activities (MedDRA) to search for communicative atypicalities within the FDA Adverse Event Reporting System (FAERS, updated June 2021). A Bonferroni 45 46 corrected disproportionality analysis (Reporting Odds Ratio) was separately 47 performed on spontaneous reports involving psychotic, affective, and non-48 neuropsychiatric disorders, to account for the confounding role of different underlying 49 conditions. Drug adverse event associations not already reported in the SIDER 50 database of labeled adverse drug reactions (unexpected) were subjected to further 51 robustness analyses to account for expected biases.

52 **Results:** A list of 291 expected and 91 unexpected potential confounding 53 medications was identified, including drugs that may irritate (inhalants) or desiccate 54 (anticholinergics) the larynx, impair speech motor control (antipsychotics), induce 55 nodules (acitretin) or necrosis (VEGFR-inhibitors) on vocal cords, sedatives and 56 stimulants, neurotoxic agents (antiinfectives), and agents acting on neurotransmitter 57 pathways (dopamine agonists).

58 **Conclusions**: We provide a list of medications to account for in future studies of 59 communication-related markers in affective and psychotic disorders. The current test 60 case illustrates rigorous procedures for digital phenotyping, and the methodological 61 tools implemented for large scale disproportionality analyses can be considered a 62 roadmap for investigations of communication-related markers in other clinical 63 populations.

64

Introduction

The confounding role of medications on communication-related markers 65 66 Affective and psychotic disorders have long been associated with atypical 67 communicative patterns - e.g., decreased emotional expression and flat prosody 68 (Cummins et al., 2015; Parola et al., 2020). This awareness is widely used during the 69 assessment of the disorders, and is increasingly investigated through automated 70 voice and content analysis (Faurholt-Jepsen et al., 2018; Hansen et al., 2021; Low et 71 al., 2020; Parola, Lin, et al., 2022; Parola, Simonsen, et al., 2022). The combination 72 of new powerful forms of machine learning, pervasive smartphone data collection, 73 and other sources of big data will allegedly identify historically elusive markers for 74 affective and psychotic disorders and therefore enable more reliable diagnoses, 75 continuous evaluation of symptoms, and perhaps even personalized treatment 76 (Arevian et al., 2020; Ben-Zeev et al., 2019; Cohen, Cox, et al., 2020; Cohen, 77 Schwartz, et al., 2020; Insel, 2017). However, communication is a complex 78 phenomenon and its relation to specific disorders is not straightforward, with many 79 potential confounders and ethical considerations (Albuquergue et al., 2021; Corona 80 Hernández et al., 2023; Parola, Lin, et al., 2022; Rybner et al., 2022).

Medications, which are disproportionately associated with neuropsychiatric diagnoses and their co-morbidities, can affect not only mental health but also the communicative patterns in the patient. For example, commonly used medications with anticholinergic effects (e.g., antihistamines and antidepressants) can cause reduced salivation flow (xerostomia) and sedation of the mouth, which could cause dysphonia and difficulty in articulation (Haft et al., 2015). Another example: high D2R occupancy antipsychotics are administered to patients with psychotic disorders and

88 are also associated with slower speech and increased pauses (de Boer et al., 2020). 89 Therefore, it is often not clear whether the communicative atypicalities identified as 90 behavioral markers of affective and psychotic disorders could be partially 91 confounded by medications. Unfortunately, more general investigations of the 92 associations between communicative atypicalities and medications are still sparse, 93 and no comprehensive overview is available (see Supplementary Material 1 -94 Section A for an overview of studies assessing the effect of medication on speech 95 patterns in schizophrenia).

96 Therefore, the objective of the current study was to identify a list of drugs that 97 could be associated with communicative atypicalities, which should be evaluated in 98 the future as potential confounders in communication-related markers of affective 99 and psychotic disorders. After introducing our two key sources of information-100 clinical-trial-based information (SIDER, Kuhn et al., 2016) and spontaneous reports 101 (FAERS, FDA, 2022)-, four common causal mechanisms underlying observed 102 associations between drugs and adverse events are briefly discussed. We present 103 how the potential biases highlighted can be accounted for in the analyses before 104 detailing materials and methods. Finally, the resulting list of drugs associated with 105 communicative atypicalities are reported and discussed.

106 Information sources

107 As medications are tested in clinical trials, adverse drug reactions are 108 evaluated, and if the drug is approved for market distribution (marketing 109 authorization) these adverse reactions are reported by law in the insert of the 110 medication package (Poluzzi et al., 2012), also known as prescribing information or 111 summary of product characteristics. However, as the drug is used outside of clinical

112 trials (post-marketing phase) unexpected adverse drug reactions are often detected. 113 For example, an adverse drug reaction could arise in populations not investigated in 114 clinical trials (e.g., older or younger cohorts, pregnant women, patients with 115 additional comorbidities). In addition, multiple drugs are often administered together 116 (polytherapy), and an adverse drug reaction could arise from their interaction. Such 117 suspected adverse reactions to drugs can be spontaneously reported to the 118 regulatory agencies by physicians, marketing authorization holders, and the general 119 public. Disproportionality analyses are statistical techniques developed to detect 120 patterns within spontaneous reporting systems' databases in an attempt to provide a 121 more comprehensive safety profile of medications (Alves et al., 2013).

122 Clinical trials and disproportionality analyses have complementary strengths. 123 Clinical trials have obvious advantages, primarily that, by carefully selecting 124 homogeneous samples and randomly distributing them across interventions, they 125 remove many possible confounders and provide a strong causal assessment. 126 Conversely, spontaneous reports can cover a much broader variety of patients and 127 drug uses, including adverse reactions that are commonly underreported during 128 clinical trials, although certain causality cannot be inferred due to confounders and 129 lack of randomization. For instance, rashes are easy to observe, and arrhythmias 130 could be fatal. Therefore, both are relatively prominent in clinical trial reports (Loke & 131 Derry, 2001; Seruga et al., 2016) as compared with symptoms such as raspy vocal 132 quality, or mispronunciations of speech sounds. However, communication 133 impairments can be disabling from the patient's point of view, and therefore be more 134 likely to be spontaneously reported, as has been shown for stuttering (Ekhart et al., 135 2021; Inácio et al., 2017; Toki & Ono, 2018; Trenque et al., 2021).

136 Pharmacovigilance has long acknowledged that spontaneous reports provide 137 very noisy information riddled with well-known biases. For example, reports may be 138 incomplete or duplicated, lack quality control of the information provided (e.g., 139 patients do not have the right language and knowledge to accurately describe their 140 symptoms), contain potential biases, and may ignore external factors such as the 141 novelty of a drug and how media coverage of adverse reactions affects the number 142 of reports (Poluzzi et al., 2012; Raschi et al., 2018; Wisniewski et al., 2016). In other 143 words, causal connections between drugs and adverse reactions should not be 144 established based solely on spontaneous reports. Nevertheless, by taking these 145 biases into account, disproportionality analyses can generate hypotheses for further 146 investigation in analytical studies (cohort and case-control studies). Finally, with 147 large enough sample sizes, there are methods for approximately estimating the 148 causal effect of drugs in observational studies by adjusting for these newly 149 considered confounders through confounding-adjustment methods (Hernán, 2018). It 150 should be noted that package inserts and spontaneous reports do not exhaust the 151 possible sources of information on adverse drug reactions, which would include, for 152 instance, the scientific literature, health records, and clinical expertise in general.

153 Causal models underlying drug adverse event associations.

Disproportionality analyses identify adverse events that are more frequently present in reports about a given drug than in reports not containing that drug. However, the observed association could be generated through different causal mechanisms, with four common ones represented in **Figure 1**.

158 The first possible causal model is simply that the adverse event is indeed 159 caused by the drug (an **Adverse Reaction** to it; DAG A). For example, administering

anticholinergic drugs often results in reduced salivation flow (xerostomia) and
sedation of the mouth, which can cause speech impairment (Haft et al., 2015).

162 However, the association might also result from **Reverse Causality** (DAG B): the drug is taken because of the event (e.g., to treat it)¹. For example, botulinum 163 toxin is approved to treat spasmodic dysphonia, and antipsychotics are administered 164 165 off-label to reduce stuttering (Maguire et al., 2020). These drugs can be reported as 166 associated with a speech impairment because, for example, the lack of specific fields 167 for symptoms of the underlying condition or for comorbidities often generates 168 ambiguity in the reported information. Furthermore, when therapy does not reduce 169 symptoms, reports might incorrectly record the indication for use (pre-existing 170 stuttering) as an adverse reaction (after drug administration, stuttering is still there).

171 A third common possibility is the so-called "common cause" or fork (Pearl, 172 2009). Here the underlying condition is causing both the prescription of the drug and 173 the adverse event, without there being any direct causation between the latter two 174 (**Confounding by Indication**; DAG C). For example, psychotic disorders can involve some degree of communication impairment (e.g., alogia, i.e., reduced and vague 175 176 speech, or disorganized speech), as well as the administration of antipsychotics. Therefore, when assessing all reports on FAERS, one might find an association 177 178 between communication impairments and antipsychotics simply due to their co-179 presence, even if there were no direct causal association. Another example of the 180 "common cause" problem is seen with gastroesophageal reflux, for which proton 181 pump inhibitors (PPI) are administered. Acid reflux can also affect the larynx and 182 vocal cords, resulting in dysphonia (Lechien et al., 2017), which would then appear 183 to be associated with PPI even in the absence of a direct causal link.

¹ While the adverse event is causing the prescription of the drug, the drug itself could be affecting the symptom (e.g., diminishing it) and therefore a more nuanced causal model than this simplified DAG would have to include bidirectional causal arrows, or a temporal dimension to causation.

A fourth common possibility is that the adverse event is indeed an adverse reaction, but to a different concomitant drug also prescribed due to the underlying condition (**Confounding by Concomitant**; DAG D). For example, diuretics are usually administered in conjunction with angiotensin-converting enzyme inhibitors (ACEI), which are known to cause bradykinin-related cough and laryngeal irritation. Therefore, diuretics might appear to be associated with dysphonia, even if the latter were exclusively due to ACEIs.

Finally, the relationship between a drug and an event may also not be reducible to one DAG only. Botulinum toxin may indeed be used to treat spasmodic dysphonia (DAG B), but it was also subject to a warning by the FDA because the systemic spread of the toxin can lead to temporary flaccid paralysis and related dysphonia (DAG A) (Kuehn, 2009).

196 From causal models to statistical analyses

197 When disproportionality analyses identify an association between a drug and 198 an adverse event, how can one discriminate between the possible causal 199 mechanisms? It turns out that there is no replacement for clinical and scientific 200 knowledge, including evidence from previous studies, clinical expertise, and 201 informed mechanistic hypotheses. This knowledge must play a meta-statistical role 202 in guiding the construction of statistical analyses. In other words, it is up to clinically 203 and scientifically informed disproportionality analyses, not statistics alone, to identify 204 plausible directions of causality and the necessary follow-up studies.

205 Specifically, reverse causality (DAG B in Figure 1) could be anticipated by 206 carefully considering which drugs are used to treat the condition investigated. For 207 instance, one could run analyses only on reports that do not include drugs used to

medRxiv preprint doi: https://doi.org/10.1101/2022.09.05.22279609; this version posted April 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

208 treat communication disorders. Similarly, clinical expertise can identify whether 209 underlying conditions are also likely to cause the adverse events of interest 210 (Confounding by Indication, DAG C in Figure 1). This is the case of psychotic and 211 affective disorders being associated with communicative impairments (e.g., flat 212 prosody for both types of disorders, and semantic incoherence for psychotic 213 disorders). A solution to this bias is to explicitly include the common cause in the 214 model ("blocking the backdoor path" (Pearl, 2009)), for instance, by analyzing the 215 populations separately: in our case, this implies separately analyzing individuals with 216 affective disorders, individuals with psychotic disorders, and individuals without any 217 neurologic medication in order to test whether patients with, e.g., affective disorders 218 on vs. off a specific drug display higher rates of the adverse event of interest. By 219 looking at reports for individuals not taking any neurologic medication, it is possible 220 to exclude (and therefore correct for) psychiatric patients as well as other 221 communication-impairing conditions such as anxiety, Parkinson's disease, and 222 dementia. This analysis is, of course, a first approximation: affective and psychotic 223 disorders are complex conditions with very heterogeneous clinical profiles, 224 comorbidities, and therapies. To move one step further, one could identify other 225 underlying comorbid conditions likely to cause communicative impairments and 226 produce a control analysis where all these conditions are excluded. Similarly, in the 227 Confounding by Concomitant case (DAG D in Figure 1), one could identify drugs 228 known to produce communicative impairments and exclude reports containing these 229 drugs from the analysis. This also deals with what is known as "competition bias" 230 (Raschi et al., 2018): known adverse drug reactions are easier to detect and 231 therefore reported more frequently. Thus, established adverse drug reactions result

in stronger associations, which mask the less reported unexpected ones. Whenknown signals are removed, new associations may become visible.

While these techniques provide information about potential mechanisms, they do not guarantee accurate causal inference. Nevertheless, they contribute to the collective construction of more accurate knowledge on the relationship between drugs and communicative impairments by providing hypotheses to be explored and assessed in future investigations.

239

Methods

240 Overview of the analyses

The general pipeline of the analysis is represented in **Figure 2**, the details of which are explained in the following paragraphs.

243 Definition of search terms

244 We relied on two information sources: SIDER for clinical trial reports of 245 adverse drug reactions and FAERS for spontaneous post-marketing reports. Both 246 sources employ a standardized hierarchical lexicon to code for adverse events, the 247 Medical Dictionary for Regulatory Activities or MedDRA® (an international medical 248 terminology developed under the auspices of the International Council for 249 Harmonisation of Technical Requirements for Pharmaceuticals for Human Use – 250 ICH). In MedDRA, the highest organization level is the System Organ Class (SOC, 251 e.g., nervous system vs. vascular disorders), followed by the High-Level Group 252 Terms (HLGTs, e.g., neuromuscular vs. neurological disorders), followed by High-253 Level Terms (HLTs, e.g., muscle tone abnormal vs. motor neuron disease) and 254 Preferred Terms (PTs, e.g., hypertonia vs. hypotonia). Both SIDER and FAERS code 255 their adverse events as preferred terms.

256 The MedDRA lexicon has some limitations that are important to acknowledge. 257 First, the MedDRA does not always include the most adequate terms to report a 258 given adverse event; therefore, some events are less likely to be reported or are 259 reported relying on only partially relevant terms. Second, the same event may be 260 reported using different MedDRA terms, often coded in different branches of the 261 MedDRA dictionary. For instance, speech sound disorder is coded as a psychiatric 262 event among "communication disorders and disturbances", while dysphonia is coded 263 as a respiratory event among "respiratory, thoracic and mediastinal disorders". Third, 264 and even more concerning is the limitation ensuing from the inconsistency between 265 the MedDRA and different relevant conceptual frameworks to understand 266 communicative impairments. The current study must rely on the MedDRA lexicon, 267 since both its information sources - SIDER and FAERS - code their adverse events 268 as MedDRA preferred terms. However, caution is needed in interpreting MedDRA 269 terms in this study. The MedDRA has been developed to facilitate the identification 270 of signs and symptoms - emerging as drug related adverse reactions – by a broad 271 range of users with a diverse set of expertise: from clinical practitioners to patients 272 and caregivers. Therefore, its terms do not easily map onto other very relevant 273 frameworks, such as the categories of communication impairments as investigated 274 within psychotic and affective disorders, and the nosological entities of the speech 275 and language pathology community, built to systematize knowledge on commonly 276 co-occurring signs and symptoms and their underlying mechanisms. For instance, 277 while impairments in prosody are commonly considered a speech motor control 278 issue in the domain of speech and language pathology, in the study of affective and 279 psychotic disorders it is associated with flat and blunted affect, that is, with emotional

280 aspects of the conditions. This implies differences in how prosody-related281 impairments would be categorized.

282 In order to partially overcome these limitations and to tailor the categories to 283 the question at hand, good pharmacovigilance practices rely on the so-called 284 Standardized MedDRA Queries (SMQs), which are expert-validated search queries 285 that aggregate many partially overlapping preferred terms across the MedDRA to 286 identify and retrieve cases of interest. In the absence of an SMQ for communicative 287 impairments, six clinical and domain experts (pharmacovigilance experts, speech-288 language pathologists, psychologists, and experts on voice markers of affective and 289 psychotic disorders; see the list of co-authors) independently clustered the 290 communicative PTs based on semantic overlapping, and disagreements were 291 discussed among the team until resolved. The multidisciplinary team developed the 292 clusters considering that diverse and not necessarily expert reporters may use 293 multiple terms to identify the same communicative impairment. Additionally, we 294 excluded from disproportionality analysis generic PTs (e.g., speech disorder), which 295 often imply low specificity in the report and could in principle indicate any 296 communicative impairment.

297 The FDA Adverse Event Reporting System (FAERS)

The United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) collects worldwide spontaneous reports of suspected adverse drug reactions and offers the highest accessibility to the public for customized analyses. Specifically, its raw quarterly data include demographic, therapeutic, and outcome details for each individual report. The reaction (adverse

event) and indication (why the drug was administered) fields are standardized using
 MedDRA preferred terms.

The entire FAERS - Quarterly Data (FDA, 2022) (January 2004 to June 2021) 305 306 was downloaded and pre-processed to remove duplicate reports and standardize 307 PTs and drug names. For the standardization of PTs, we used MedDRA 24.0. For 308 the standardization of drug names, we used the WHO drug dictionary accessed in 309 March 2020 and iteratively integrated to include newly marketed active ingredients. 310 Furthermore, drug names were linked to their specific code from the Anatomical 311 Therapeutic Chemical (ATC) hierarchical classification (2022 version) to allow group 312 visualization of similar drugs. Because individual substances can have multiple 313 codes related to distinct indications of use or administration routes, we selected only 314 one code for each active ingredient using a semi-automatic prioritizing algorithm 315 (Gaimari et al., 2022).

316 Exposure of interest

317 In order to identify medications associated with communicative impairments and deal with possible "common cause" biases (DAG C in Figure 1), we separately 318 319 investigated three clinical populations: patients with a) affective, b) psychotic 320 conditions, and c) without any neurologic medications (i.e., likely without any 321 neuropsychiatric conditions, hereafter termed non-neuropsychiatric reports). To 322 identify patients with psychotic and affective conditions we selected all reports that 323 recorded, as a reason for using drugs, any PT (for example, 'schizophrenia') 324 belonging to the HLGTs for psychotic disorders ("schizophrenia and other psychotic 325 disorders") and affective disorders ("manic and bipolar mood disorders and 326 disturbances" and "depressed mood disorders and disturbances"). To identify

patients without neuropsychiatric conditions, we selected all reports that did not
 include any neurologic drug (according to the ATC) nor any psychotic or affective
 preferred term. The results of the selection procedure are displayed in the
 Supplementary Material 1 – Section C – Figure S1.

331 Descriptive analyses were performed to characterize cases (displaying 332 communicative impairments) vs. non-cases separately in the three populations of 333 interest, with a particular focus on demographics, concomitants, co-reported events, 334 and comorbidities (Supplementary Material 1 Section C). Differences between cases 335 and non-cases may point to susceptibilities and potential biases not a priori 336 acknowledged. For example, if we find that older people are more represented in 337 cases than non-cases, this may point to a potential bias related to a higher frequency 338 of speech disorders in the elderly.

339 Disproportionality analyses for drug-event association detection

340 Disproportionality analysis (the analysis of a reliably more frequent reporting 341 of an adverse event in presence of a drug than in presence of any other drug, Figure 342 2 – Step 1) was performed following good signal detection guidelines (Wisniewski et 343 al., 2016). Using a contingency table 2x2, we calculated the Reporting Odds Ratio 344 (ROR) whenever at least 10 cases of the event investigated co-occurred with the 345 drug investigated. In fact, when few cases have been collected, the probability of 346 detecting spurious associations is high. Considering a threshold of 10 cases allowed 347 us to reduce this risk at the cost of missing some true associations for which not 348 enough cases had yet been collected (e.g., for particularly novel drugs), and can be 349 seen as an alternative to other conservative methods, such as the information 350 component (Norén et al., 2013). The ROR was deemed significant when the lower

limit of its 95% confidence interval was greater than 1. In other words, we report a
potential association when the adverse event is more likely to be reported together
with the drug of interest than with any other drug but the one analyzed.

We performed a disproportionality analysis evaluating associations between drugs (from the ATC 2022 classification, excluding mineral supplements and drugs included in the 'Various' class) and communication-related adverse events (subclusters of overlapping terms as identified in **Table 1**). The analyses were run on all reports involving a) affective and b) psychotic disorders, and c) non-neuropsychiatric reports. To filter out likely spurious associations, results were subjected to Bonferroni correction.

361 The Side Effect Resource (SIDER)

The Side Effect Resource is a public database that grants free access to the information contained in the package inserts, that is, the official information on a drug and its uses, in particular its side effects, compiled and distributed by the drug manufacturers. Package inserts are text-mined, and the information retrieved is coded using the ATC classification for medications and the MedDRA classification for adverse events.

For each subquery of potential adverse reactions, we searched the specific preferred terms. We considered the identified medications as expected associations (Figure 2 – Step 2), which did not require further discussion of potential biases and causal mechanisms. The associations found in FAERS but not present in the SIDER were considered unexpected and were further assessed for potential causal confounding (Figure 2 – Step 3).

374 Robustness Analyses

375 Drugs unexpectedly associated with the sub-queries investigated were 376 stratified according to expected biases (Figure 2 – Step 4) through clinical 377 reasoning and according to the causal inference framework discussed in the 378 introduction (paragraphs 1.3 and 1.4). We accordingly separated the associations 379 into uncontroversial ones (plausible adverse reactions, Figure 1, DAG A, for which 380 no specific confounder was expected), potential reverse causality (Figure 1, 381 DAG B), potential confounding by indication (Figure 1, DAG C), and by concomitant 382 (Figure 1. DAG D). Robustness analyses adjusted the estimates for 383 possible confounders (Figure 2 – Step 5): excluding reports with the communicative 384 impairment among indications or restricting the investigation to a specific indication, 385 to account for reverse causality bias (DAG B; Robustness Analysis 1); excluding 386 reports with pathologies that may be responsible for indication bias (DAG C; 387 Robustness Analysis 2), at least for drugs that are approved for multiple indications; 388 excluding reports with the drug responsible for the ambiguity to account for the 389 concomitant bias (DAG D; Robustness Analysis 3). The procedure applied is 390 documented in Supplementary Material 1 – Section D.

391 Aggregating Results

392 The expected adverse drug reactions from the SIDER and robust unexpected 393 associations from the FAERS were aggregated in a list per each main cluster of 394 overlapping PTs, Figure 2 – Step 6. To provide a detailed overview of the results, we 395 visualized each list as a table showing expected and previously unexpected adverse 396 reactions ATC hierarchical classification organized according to the 397 (see Supplementary Material 1 – Section D).

To provide a more general overview of the drug classes that should be considered for the analysis of communication-related markers, we built a heat map showing the associations at the third level of the ATC classification (e.g., antipsychotics, antihistamines, and antidepressants; see the public repository (M. Fusaroli & Fusaroli, 2021) for a collated heatmap at the level of single active ingredients).

404

Results

405 MedDRA query for case retrieval

We defined nine clusters of overlapping MedDRA PTs referring to communicative 406 407 impairments. For simplicity, we named the clusters with reference to the semantic 408 overlap and specific concerns (communicative impairments in affective and 409 psychotic disorders) that guided the aggregation: related to 1) dysphonia, 2) speech 410 motor control disorders, 3) prosody, 4) aphasia, 5) tachyphrenia, 6) bradyphrenia, 7) 411 abnormal reasoning, 8) stereotypy, and 9) incoherence (seeTable 1). Sixteen of the 412 communicative PTs were excluded from clustering and the subsequent analyses. It 413 is important to note that the clusters might not be entirely coherent with current uses 414 of the terms in the speech and language pathology community, but they were the 415 result of an interdisciplinary consensus, and they will be discussed and clarified 416 where they could generate misunderstandings.

417 Populations of interest

418 We selected three populations of interest: 302,000 reports involving affective 419 disorders, 11,631 psychotic disorders, and 7,703,183 non-neuropsychiatric 420 disorders. A detailed presentation of the number of cases (reports with

421 communication-related adverse events) and non-cases is presented in the
422 Supplementary Material 1 – Section C Figures S1-S5 and Table S2.

423 Expected and Unexpected Solid Associations

Disproportionality results and effect size for each cluster and each population are reported in the Supplementary Material 2. We detected both expected – according to the SIDER - and unexpected drug associations and performed robustness analyses on the latter ones. The result was a list of 291 expected and 91 unexpected potential confounding medications. Emerging results are shown in Supplementary Material 1 -Section C (Tables S3-S9, Figure S6). No association was found for the prosody and abnormal reasoning clusters.

We detected 72 drug classes (ATC third level) associated with a 431 432 disproportional reporting of the dysphonia cluster: 53 were already expected based 433 on the SIDER, 10 classes included both drugs already reported in the SIDER and 434 unexpected drugs (integrated classes) and 9 were entirely unexpected. Restricting to 435 strong signals (i.e., disproportions significant after the Bonferroni correction) in the 436 non-neuropsychiatric population, the highest number of cases involved inhalants -437 fluticasone (4669 cases, ROR = 10.48, 95% CIs = [10.14-10.81]), salmeterol (3099, 438 12.16 [11.71-12.63]), and salbutamol (2434, 5.52 [5.29-5.76]), while the highest 439 lower limits of the 95%CI of the ROR concerned two VEGFR-inhibitors –regorafenib 440 (530, 22.25 [20.29-24.35]) and axitinib (437, 14.27 [12.92-15.37]) and salmeterol. 441 The many anticholinergic drugs already present in the SIDER were integrated with 442 unexpected signals for umeclidinium (an inhaled bronchodilators), rupatadine and 443 fexofenadine (antihistamines). Among the robustness analyses implemented, we 444 accounted for reverse causality (DAG B: botulinum toxin excluding its use for

spasmodic dysphonia(Faham et al., 2021)), confounding by indications (DAG C:
antihistamines restricted to urticaria, to exclude the confound due to asthma) and
concomitants (DAG D: cardiovascular agents excluding angiotensin-converting
enzyme inhibitors; beta agonists excluding inhalants).

449 We detected 37 drug classes associated with a disproportional reporting of 450 the speech motor control cluster (17 expected, 10 integrated, 10 unexpected). The 451 most numerous cases concerned immunomodulators used in multiple sclerosis -452 natalizumab (770, 4.48 [4.16-4.82]) and interferon beta-1a (674, 3.62 [3.34-3.91]) -453 and a selective calcium channel blocker – amlodipine (376, 2.05 [1.84-2.27]). Drugs 454 with the highest lower limit were anti-infectives: vidarabine (20, 71.42 [42.66-455 113.63]), valaciclovir (334, 12.14 [10.84-13.55]) and metronidazole (309, 9.48 [8.44-456 10.63]).

A total of 51 drug classes were associated with the aphasia cluster (19 expected, 10 integrated, 22 unexpected), with the most numerous being natalizumab (872, 5.54 [5.16-5.94]), interferon beta-1a (643, 3.71 [3.42-4.02]), and levothyroxine (327, 1.57 [1.4-1.75], and the highest disproportionalities being with antineoplastic such as CAR-T engineered cells used to treat hematologic neoplasia –axicabtagene ciloleucel (114, 43.68 [35.78-52.8]) and tisagenleceleucel-t (58, 24.5 [18.52-31.84])– and avapritinib (20, 18 [10.33-26.44]).

464 Concerning the stereotypy cluster, we did not find any unexpected signal and 465 only four expected drug classes: antineoplastic (ifosfamide), antiepileptic 466 (topiramate), antiepileptic (phenelzine and bupropion), and contrast agents 467 (iopamidol). The only strong signal was with interferon beta-1a in non-468 neuropsychiatric patients (20, 6.12 [3.65-9.73]).

A total of 12 drug classes were associated with the tachyphrenia cluster (4 unexpected, 2 integrated, 6 expected). We observed associations based on only few cases, the greatest being clarithromycin (49, 22.38 [16.43-29.8]), levothyroxine (47, 2.29 [1.67-3.07]) and ivermectin (40, 99.9 [70.83-137.18]), with the highest disproportionalities for ivermectin, clarithromycin and niraparib (11, 10.54 [5.24-18.94]).

A total of 10 drug classes were associated with the bradyphrenia cluster (2 unexpected, 2 integrated, 6 expected), the most common drugs being natalizumab (105, 4.65 [3.77-5.67]), levothyroxine (85, 2.97 [2.36-3.7]) and interferon beta-1a (65, 2.6 [2-3.34]), the strongest signals being with lorcaserin (17, 40.85 [23.67-65.71]), finasteride (33, 11.9 [8.16-16.79]) and natalizumab.

Finally, 44 drug classes were associated with the incoherence cluster (34 expected, 4 integrated, 6 unexpected), the more numerous substances being levothyroxine (237, 1.9 [1.67-2.17]), interferon beta-1a (213, 1.98 [1.72-2.27]) and montelukast (200, 5.58 [4.82-6.43]), and the highest disproportionalities being those with anti-infectives –mefloquine (33, 36.26 [24.8-51.28]), zanamivir (14, 11.95 [6.51-20.13]) and oseltamivir (62, 6.47 [4.95-8.31]).

486

487

Discussion

488 Overview

Given the increased focus on communication-related markers of affective and psychotic disorders, there is an increased need for a careful overview of how medications could act as confounders. The current study rigorously combined evidence from drug package inserts with post-marketing disproportionality analyses

and relied on causal inference techniques to account for potential biases, in order toprovide a first attempt at such an overview.

In the following subsections, we discuss how to interpret and use these findings and methods in the broader context of digital phenotyping trying to identify markers of neuropsychiatric conditions: discussing expected and unexpected potential adverse reactions as they relate to the specific context of communicationrelated markers of psychotic and affective disorders; presenting the limitations and possibilities of our approach; and discussing possible realistic uses of the list in future research.

502 Known and unexpected adverse reactions

503 The final list of potential confounding drugs for communication-related 504 markers encompasses both expected (i.e., described in the package insert) and 505 unexpected associations. Some of the expected associations are already discussed 506 in the literature on communication-related markers. For example, the effects of 507 antipsychotics and antidepressants have been directly investigated when evaluating 508 communication-related markers (Cohen et al., 2017; Cummins et al., 2015; de Boer 509 et al., 2020; Püschel et al., 1998; Sinha et al., 2015). However, even these expected 510 associations are not routinely considered in the actual analysis of communication-511 related markers of psychotic disorders (Parola et al., 2020), and when they are, the 512 results are inconclusive (Parola, Lin, et al., 2022; Parola, Simonsen, et al., 2022).

513 In other cases, we found unexpected associations with drugs from already 514 known classes (integrated findings, that is, drugs from the same class were already 515 known to associate with the adverse reaction). For instance, clonazepam (an 516 antiepileptic, also used to treat anxiety) being associated with the aphasia cluster

and for antineoplastic agents (mainly VEGFR-inhibitors) with the dysphonia cluster.
Some drugs' package inserts, in fact, did not list all the possible preferred terms that
could be used to describe their side effects. This led to the classification of certain
expected drug reactions as unexpected (e.g., the package inserts for haloperidol
only mentioned motor control disorders, but not speech motor control disorders),
even if the scientific literature or clinical practitioners may already be aware of them.

523 Other associations are more unexpected. Medications used to treat cancer, 524 such as plant alkaloids, cytotoxic antibiotics, protein kinase inhibitors, and 525 monoclonal antibodies, emerge as potential causes of aphasia, which are not 526 reported in the SIDER database. Crucially, since there is at least some evidence of 527 increased cancer risk in schizophrenia (Nordentoft et al., 2021), we could expect a 528 more common use of these drugs in patients with schizophrenia than in controls. 529 Therefore, the adverse reaction could influence how well a predictive model could 530 detect psychotic disorders from speech or language patterns, at least in complex 531 machine learning models. Nevertheless, these drugs have never been mentioned -532 to our knowledge - in previous studies of communication-related markers as possible 533 confounders.

534 Drug-induced communicative impairment mechanisms

We contextualized the drugs identified as possible confounders for communication-related markers according to their plausible mechanism of action (see **Figure 3**). Indeed, biological plausibility is one element of credibility for hypotheses emerging from disproportionality analyses. Furthermore, understanding the mechanism underlying drug-induced communication atypicalities may allow to identify other plausible involved drugs not detected in our study (e.g., because of

541 unaccounted for biases, or because still not on the market). Finally, the knowledge of 542 exactly how communication-related markers are affected by each drug may be 543 included in machine learning algorithm to provide more reliable predictions.

544 The role of drugs in inducing phonatory impairment, often reported as 545 hoarseness, is already consolidated for multiple drugs (see **Table S3**). The primary 546 responsible - in terms of numbers - is plausibly anticholinergic toxicity because of 547 xerostomia and larynx desiccation (antimuscarinic inhaled bronchodilators, 548 spasmolytics, drugs for overactive bladder, muscle relaxants, antidepressants, 549 antipsychotics, antihistamines) (Haft et al., 2015). Notably, we observed a signal for 550 second and third generation antihistamines which, trespassing less the blood brain 551 barrier, preserve from central anticholinergic toxicity (mainly sedation) but may 552 nonetheless exert their peripheric effect on salivary glands. The drying effect of 553 diuretics, secondary to hypovolemia, is controversial (Schwartz et al., 2009). Instead, 554 drug-related laryngeal irritation is an established common condition, whether 555 because of inhalant drugs (corticosteroids – especially dry powders (Galván & 556 Guarderas, 2012) – beta-agonists and mast-cell stabilizers), drugs inducing cough 557 such as angiotensin converting enzyme inhibitors (Bangalore et al., 2010), or improperly taken bisphosphonates (Hanna et al., 2012). In fact, for inhalants and 558 559 other respiratory drugs (xanthines, leukotriene receptor antagonists, respiratory 560 monoclonal antibodies), it is often difficult to differentiate between the role of the drug 561 and the underlying disease.

562 Drug-induced **organic lesions of vocal cords** may also be responsible for 563 dysphonia, as in the case of hemorrhages induced by anti-thrombotics, anti-564 inflammatories, and 5-phosphodiesterase inhibitors (Stachler et al., 2018), reversible 565 nodules due to excessive granulation response induced by acitretin and isotretinoin

566 (Busso & Serrano, 2005; Kim et al., 2006), or necrosis due to the antiangiogenetic 567 activity of VEGFR-inhibitors (Kudo et al., 2018; Melo et al., 2019; Motzer et al., 2013; 568 Saavedra et al., 2014; Sulibhavi et al., 2020; Wen et al., 2018). Sex hormones may 569 also be involved (Zamponi et al., 2021), as for androgens and antigonadotropins 570 inducing vocal cords thickening and voice deepening through androgen receptors on 571 (Chadwick et al., 2021). Furthermore, antineoplastics the larynx and 572 immunomodulating drugs are also known to be associated with dysphonia, plausibly 573 due both to the cytotoxic (Berretta et al., 2004) and immunomodulating role of the 574 drug (Benfaremo et al., 2018; Bruno et al., 2021), to the disease (Gavrila et al., 575 2015), and to concomitant radiotherapy (Villari & Courey, 2015).

576 Finally, an impairment in phonation may be due to extrapyramidal **dystonia** 577 (mainly antipsychotics, but also dopamine antagonist antiemetics such as 578 metoclopramide, that was subjected to an FDA black box warning for dyskinesia, 579 with involuntary movements of the tongue) or to botulinum-related **flaccid paralysis** 580 (a black box warning for systemic toxicity was added to the package insert on 2009).

581 Other drug classes expected based on SIDER are insulins, 5HT3 antagonist 582 antiemetics, antimycotics, antivirals, dopamine agonists, cholinergic drugs, cough 583 preparations, antiepileptics, analgesics and anesthetics, anxiolytics and sedatives, 584 and cardiovascular drugs. These drug are themselves not totally free of confounding. 585 such as confounding by indication (DAG C: diabetes (Hamdan et al., 2013), cough, 586 and vomit) and reverse causality (DAG B: proton pump inhibitors - for dysphonia 587 supposedly due to laryngo-esophageal reflux (Lechien et al., 2017; Ruiz et al., 2014) 588 and antibiotics – for dysphonia supposedly due to respiratory infections (Stachler 589 et al., 2018)).

590 The role of drugs in inducing speech motor control impairment is already 591 consolidated for dopamine antagonists-related acute dystonia and tardive dyskinesia 592 (antipsychotics), agents inducing sedation and reduced speech motor control 593 (anxiolytics, antiepileptics, opioids, antidepressants, anticholinergic drugs, muscle 594 relaxants), neurotoxic drugs (anti-infective, antineoplastic and immunomodulator 595 agents), dopamine agonists (Craig-McQuaide et al., 2014), and drugs interacting 596 with catecholaminergic and GABAergic pathways (Ekhart et al., 2021). We also 597 observed an association with antineoplastics and immunomodulators – plausibly due 598 to their neurotoxicity – and with cardiovascular agents and hormones. Interestingly, 599 the signal for antithrombotic medications persisted when excluding ischemic and 600 unspecified stroke cases. Even if we cannot exclude reverse causality and indication 601 bias, this signal may point to the possibility of drug-induced cerebral hemorrhages.

602 Multiple cases of iatrogenic aphasia have been reported in the last decade 603 (Rizwan et al., 2021), often concerning reversible conditions induced by 604 immunomodulators, chemotherapy and fluoroquinolones-related neurotoxicity (Belin 605 et al., 2020; Bennett et al., 2019; Carl et al., 2015; Higa et al., 1995; Patel et al., 606 2015). A similar toxicity may also manifest because of the increased permeability of 607 the blood brain barrier due to contrast media, potentially allowing endogenous and 608 exogenous neurotoxins to reach the central nervous system. Dopamine antagonism 609 (Chien et al., 2017), shared by antipsychotics and the propulsive domperidone, may 610 also be responsible for aphasia, as well as antithrombotic-related hemorrhages. 611 Bradyphrenia and tachyphrenia may also be the manifestation of neurotoxicity, and 612 sedation antiepileptics. pramipexole, of (e.g., antipsychotics. lithium, 613 benzodiazepines, antidepressants, antihistamines, cannabinoids) and excitation 614 (levothyroxine, psychostimulants), respectively.

615 Limitations and future directions

616 Formalized query

In the attempt to retrieve cases of interest in the FAERS, we found an oftenambiguous lexicon covering communicative impairments. The current study explicitly formalized a MedDRA query to retrieve communicative impairments relevant to affective and psychotic disorders more systematically. This formalized query is a necessary step to focus the attention and to create a common framework for disproportionality analyses on these impairments.

623 The current query presents some limitations. First, one might more closely 624 investigate how physicians describe and report these impairments. For example, 625 common terms used by physicians to report dysphonia are acute laryngitis, 626 nonspecific dysphonia, benign vocal fold lesions, and chronic laryngitis (Stachler et 627 al., 2018), and for retrieving antipsychotic-related dysarthria cases one may search 628 also for extrapyramidal syndrome and laryngospasm. More work is needed to cover these labels and validate the results of searches that integrate them. Second, 629 630 perhaps more crucially, we observed a high proportion of communication-related 631 FAERS cases submitted by the general public. This suggests that communicative 632 adverse events might be at the same time underplayed by medical practitioners, and 633 of crucial importance to patients, caregivers, and families. In fact, we observed that 634 patients with communicative impairments tend to specify the resulting disability more 635 frequently in their reports than patients with other adverse events but the same 636 underlying condition. Third, during the definition of the query, we found several 637 inconsistencies between the clusters of relevant MedDRA terms and terminological

638 practices in the speech and language pathology community, which could create 639 unnecessary confusion.

One could also question whether FAERS' and SIDER information is 640 641 sufficiently sensitive to the kind of properties analyzed in the search for 642 communication-related markers. For example, minor acoustic atypicalities such as 643 increased jitter - low-level irregularities in voice pitch, a commonly used acoustic 644 measure in predictive, machine learning algorithms for affective and psychotic 645 disorders (Cummins et al., 2015; Parola et al., 2020) as well as for Parkinson's 646 disease (Tsanas & Arora, 2021) - might not be perceived, or at least not perceived 647 as enough of an issue, by patients and clinicians to be reported and precisely 648 labeled. This suggests that a closer collaboration of patients and practitioners – 649 crucially including speech and language pathology and communicative markers 650 experts – in developing a common and easy to use terminology and clear definitions 651 for communicative impairments would provide a substantial improvement for the 652 MedDRA lexicon.

653 Nevertheless, the construction of an initial query enables initial explorations of 654 medication-based confounders and facilitates proposals, thus representing an 655 important step in the development of a useful Standardized MedDRA Query (SMQ).

656 Causal inference

Although still uncommon in disproportionality analyses, formalized causal inference, and the use of DAGs, in particular, are a promising endeavor (Cunningham, 2021; Pearl, 2009). These tools provide a standardized framework for the formalization, visualization, and communication of confounding. These tools also provide structured and more reproducible procedures to account for at least some of the biases when designing analyses (Pearl, 2009).

663 We have built four relatively simple DAGs of the mechanisms underlying 664 observed drug event observations. Thus, we have tried to identify the most 665 problematic biases for our questions and accordingly adjusted our analyses and 666 interpretation. However, it is important to note that many biases could not be fixed 667 and that the characteristics of the reporting (often incomplete and unverified) 668 complicate attempts at causal inference. For example, proton pump inhibitors are 669 used to treat or prevent gastroesophageal reflux, a condition that may also affect the 670 larynx and vocal cords and result in laryngo-esophageal reflux disease and 671 dysphonia (Lechien et al., 2017). Therefore the causal direction (PPI to dysphonia, 672 or reflux to both PPI and dysphonia) cannot be easily identified. Further, our broad 673 focus did not permit us to delve into the richness of spontaneous reports (e.g., 674 information on concomitants, therapy regimen, co-occurring events) and to map 675 more complex scenarios (e.g., variables affecting at the same time the use of the 676 drug, the incidence of the adverse event, and the reporting of it). For example, 677 botulinum toxin has been referred to as a potential cause and treatment for 678 spasmodic dysphonia but may also temporarily cause dysphonia through muscle 679 weakening. In addition, biases, such as notoriety bias, and masking bias, adjustment 680 for the Weber effect (Raschi et al., 2018), are beyond the scope of this study but 681 should be considered when investigating specific drugs more closely. Further, 682 because of the many biases of spontaneous reporting, the comparison of the safety 683 profile of different drugs on the basis of disproportionality alone tends to be 684 unreliable and is in general not recommended (Mouffak et al., 2021).

685 Integrating additional sources

686 The main objective of spontaneous reporting systems is to collect useful data 687 to identify unexpected associations between a drug and an adverse event in a timely

and cost-effective manner. This identification enables early intervention and therefore limits the costs of drug-related harm. To effectively target currently not known safety issues, it is extremely important to integrate already acquired knowledge, which may come from the literature, or from regulatory sources primarily package inserts (FDA) and Summaries of product characteristics (EMA).

693 Databases that store this information in an easily accessible way are a 694 promising tool for large-scale analyses because reading and coding each individual 695 package insert would be extremely time consuming. The SIDER uses a natural 696 language processing algorithm to extract the information from regulatory sources 697 and has not been updated since 2016 (Kuhn et al., 2016), therefore, it plausibly 698 contains errors and outdated information. Furthermore, it may contain terms linked 699 but not coincident with the investigated events (as in the case of haloperidol), and 700 therefore our automated process may lack some expected reactions.

A worldwide database in which data for each marketed drug is compiled and regularly updated by the marketing authorization holder and stored in an accessible way would enrich both regulatory activities and disproportionality analyses. In the meantime, the use of the SIDER or similar databases may help in large-scale analyses to reduce the risk of classifying already known reactions as unexpected signals.

We cannot be sure whether some of the unexpected associations have already appeared as notes in clinical trials (but not reported in the package insert) or in subsequent scientific literature. Future work should attempt to integrate these additional sources of information. However, independent of the novelty, our list aggregates large amounts of otherwise dispersed information in an easier to consult format.

Future work could integrate additional sources of information, both as related to known associations (e.g., scientific literature) and additional clinical data (e.g., health records), to provide a more comprehensive overview. Further, different sources could be weighted according to the degree of evidence available (e.g., via Bayesian analysis).

718 Large-scale analyses

Traditional disproportionality analyses focus on at most a handful of drugs and/or adverse events (Aiello et al., 2021; Raschi et al., 2020). Thus, they can provide a fine-grained analysis of potential confounders, including a nuanced analysis of how sociodemographic variables might affect drug prescription and adverse reactions (Hoekstra et al., 2021).

724 Large-scale analyses require a broader overview, which cannot match the 725 same level of detail and discussion. The strategies we implemented to 726 simultaneously assess large sets of adverse events and drugs may help design 727 future large-scale analyses. These strategies range from correction for multiple 728 testing and automatic integration with regulatory databases, to an attempt to 729 formalize possible underlying causal mechanisms and the use of a priori expected 730 biases to implement robustness analyses. Large-scale analyses, however, provide 731 only an initial perspective and must be complemented with more detailed studies of 732 specific associations and their confounds.

733 How should this list be used?

We advocate for the list of drug confounders (Figure 3 and Supplementary Material 1 – Section D – Table S10)– whether as a cause of communicative atypicality or as a proxy of an underlying susceptibility – to be used in future studies

737 of communication-related behavioral markers by either including the presence of a 738 medication as a covariate, removing participants who take medication, or interpreting 739 results and study limitations as a function of which medications were taken. As 740 observed in multiple reviews, most studies of such markers involve small sample 741 sizes (R. Fusaroli et al., 2017; Parola et al., 2020; Weed & Fusaroli, 2020). Such 742 studies would be at a loss trying to adjust for such a large number of medications 743 and would lack reliable evidence related to all but the most commonly used ones 744 (Rocca & Yarkoni, 2021; Westfall & Yarkoni, 2016). Although a single study may still 745 check the list to identify likely cautions (e.g., much higher use of drug x in the target 746 population than in the controls), the real potential lies in the cumulative aggregation 747 of this information across studies. The key is to promote transparency of reporting 748 and record medications used by participants in individual studies, which would allow 749 future mega-analyses (R. Fusaroli et al., 2022) (aggregating datasets across studies 750 preserving individual-level data) to directly assess the impact of a large variety of 751 relevant medications.

752 Accounting for confounders is also important in machine learning studies. 753 Current reviews and perspectives on the study of communication-related behavioral 754 markers advocate the collection of larger and more diverse samples and the use of 755 state-of-the-art machine learning techniques, such as deep learning (Parola, Lin, et 756 al., 2022; Parola, Simonsen, et al., 2022; Rybner et al., 2022). In these contexts, the 757 algorithms can detect even the presence of weak confounding if it improves 758 prediction. In other words, many machine learning models are likely to recognize 759 small differences between groups they try to classify. If these differences are due to 760 higher levels of medication being used and not due to the target disorder, the models 761 may not generalize well to other samples of the disorder where the medication use is

different, which is common when changing countries and sociodemographic settings.
Accordingly, a deeper understanding of the confounders and mechanisms at work is
a key component also for more data-driven machine learning approaches, for
instance, to guide bias assessment or even to identify more rigorous pipelines (e.g.,
presenting medication-balanced validation sets).

767 Finally, this list may also help identify more general hypothesized 768 mechanisms underlying adverse events beyond a specific drug. Pharmaco-769 surveillance can thus act not only as a guide for precautionary regulatory action, but 770 also as a hypothesis generation tool for scientific research, which could lead to 771 follow-up studies involving, e.g., electronic health records (to assess adverse events 772 before and after drug administration), experimental setups, and clinical studies. For 773 instance, a more thorough investigation of the association between domperidone 774 and aphasia would be of particular interest, given the biological plausibility (i.e., its 775 activity as a dopamine antagonist) and the existence of conditions that increase the 776 blood-brain barrier permeability. This might lead to more generalizable predictions 777 regarding confounding drugs and an increased understanding of the communicative 778 features of the disorders over time.

779 Applications of the methods to other neuropsychiatric conditions

In the current study, we have focused on affective and psychotic disorders since previous research explicitly called for better investigation of medication-related confounders in identifying communication markers for these populations (Cummins et al., 2015; Low et al., 2020; Parola et al., 2020). However, with proper consideration, the list could be easily extended when assessing communicationrelated behavioral markers for other conditions such as neurodevelopmental (e.g.,

autistic spectrum disorder) and neurological (e.g., Parkinson's disease) disorders. In
particular, for Parkinson's disease, good practices to account for med-on and med-

off levodopa state already exist (e.g., Im et al., 2019; Thies et al., 2021).

789 Conclusions

Motivated by the increasing interest in communication-related behavioral markers of affective and psychotic disorders, we set out to investigate the potential role of medications in affecting communication-related markers of these disorders. We extracted the drugs already expected to cause communicative impairments from the SIDER. This paved the way for a pharmacovigilance analysis of a larger set of communication-related adverse events and drugs, controlling for prominent biases.

796 We identified a list of medications to be accounted for in future studies on 797 communication and biobehavioral markers of affective and psychotic disorders. 798 These studies should take into account: drugs irritating vocal cords and the larvnx 799 (inhalants, bisphosphonates, angiotensin-converting enzyme inhibitors); drugs 800 inducing laryngeal desiccation (anticholinergics, diuretics); drugs impairing speech 801 motor control (anxiolytics, antiepileptics, opioids, antidepressants, anticholinergics, 802 myorelaxants, antipsychotics, antiemetics), or temporarily paralyzing vocal cords 803 (botulinum toxin); drugs inducing laryngeal hypertrophy (androgens, 804 antigonadotropins) or the development of nodules on vocal cords (retinoids); drugs 805 potentially inducing necrosis (VEGFR-inhibitors) or hemorrhages in the vocal cords 806 (antithrombotics, nonsteroidal anti-inflammatories, PDE5-inhibitors); sedatives 807 (anxiolytics, antiepileptics, antidepressants, hypnotics, antihistamines, 808 cannabinoids); stimulants (psychostimulants, thyroid hormones, pramipexole); drugs 809 interacting with catecholaminergic and GABAergic neurotransmitters; neurotoxic

810 drugs (antiinfectives, antineoplastics, immunomodulators, contrast media, 811 antithrombotics).

The work showcases methodological innovations to facilitate large-scale disproportionality analyses and identifies current shortcomings, along with discussing potential causal and pathogenetic mechanisms. In particular, the existing lexicon to identify communicative adverse events is ambiguous and not well defined, perhaps due to an underappreciation of the perspectives of patients and lack of integration of experts in speech and language pathology and in communicative impairments. We advocate for future work on this.

Drugs that confound the effect between communication-related behavioral markers and psychiatric disorders are abundant. There should be concern not only for confounding drugs and comorbidities, but also non-medical substances and habits (e.g., smoking, vocal use). Here, we provide a tool for learning about and potentially adjusting for the confounders to improve digital phenotyping research.

824 Declarations

- 825 **Funding**: none
- 826 Conflicts of interest/Competing interests: RF has been a paid consultant for F.
- 827 Hoffmann La Roche.
- 828 **Ethics:** Anonymized data were collected from a publicly available database and did
- 829 not require ethics committee approval.

830 Authors' contributions: MF, AS, and RF conceived the research project. MF, SB, 831 AS, DML, AP, and RF defined the query for case retrieval. MF designed and 832 executed the statistical analysis. MF, ER, EP, and RF reviewed and critiqued the 833 statistical analysis. All the authors contributed to the interpretation of data. Regarding 834 manuscript preparation, MF and RF executed the writing of the first draft and all the 835 authors contributed to the review and critique. All authors approved the final version. 836 Acknowledgments: MF, EP and ER were supported by institutional research funds 837 (Ricerca Fondamentale Orientata). AS was supported by a Postdoctoral Fellowship 838 from the Carlsberg Foundation. AP was supported by a Marie Curie Fellowship from 839 the ERC. DML was supported by a RallyPoint Fellowship. MedDRA® trademark is 840 registered by ICH.

- 841 Data availability statement: The pharmacovigilance data are freely accessible on
- 842 the FDA website: <u>https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-</u>
- 843 FAERS.html
- 844 **Code access:** The code used is available upon request.

BIBLIOGRAPHY

Supplementary Material

Supplementary Material 1 includes an overview of the studies assessing the effect of medication on speech patterns in schizophrenia (Section A), the MedDRA Query developed for the retrieval of communication atypicalites (Section B), the features of the population investigated (Section C) and the summary of the results of the disproportionality analysis (Section D).

Supplementary Materia 2 stores all the results of the disproportionality analysis, including the effect sizes.

Figure 1 common causal mechanisms underlying drug adverse event associations.

The four diagrams (A-D) represent four possible mechanisms which can all give rise to the observed association (in the center). The diagrams are direct acyclic graphs (DAGs), that is, graphs in which the nodes (ellipses) are the observable phenomena, and the arrows are the causal connections (which can only be acyclical, that is, go one direction and not form loops). **DAG A** represents the case in which the event is an actual Adverse Reaction caused by the administration of the drug of interest. **DAG B** represents a case of Reverse Causality, in which the drug is administered to treat the adverse event but is incorrectly reported. **DAG C** represents a case of Confounding by Indication, in which the underlying condition that justifies the use of the drug also more frequently induces the adverse event. **DAG D** represents a case of Confounding by Concomitant, in which the adverse event is a reaction to a co-administered drug (administered for the same condition or a related comorbidity).

Figure 2 - Analysis pipeline. Each step of the analysis is represented as a block and arrows indicate the flow of data from one step to the other. Descriptions of each step are provided in text.

Figure 3 – Summary of drug-related communicative atypicalities' plausible **mechanisms.** Created with BioRender.com.

 Table 1 – MedDRA Query for the retrieval of communicative atypicalities reports. We identified multiple sub-queries including semantically overlapping MedDRA Preferred Terms. The clusters were obtained on the basis of semantic overlapping, and therefore on the possibility that the reporters may have used interchangeably different terms, rather than with a reference to existing speech and language pathologies.

Cluster	Ister MedDRA Preferred Terms		
Cluster 1 (dysphonia- related)	Dysphonia Dysphonia psychogenic Muscle tension dysphonia	Spasmodic dysphonia Aphonia Aphonia psychogenic	Phonastenia Stridor
Cluster 2 (speech motor control-related)	Dysarthria Dyslalia	Dysphemia	
Cluster 3 (prosody- related)	Aprosody Dysprosody		
Cluster 4 (aphasia- related)	Aphasia Primary progressive aphasia		
Cluster 5 (tachyphrenia-related)	Logorrhea Pressure of speech	Flight of ideas Tachyphrenia	
Cluster 6 (bradyphrenia-related)	Poverty of speech Bradyphrenia	Lack of spontaneous speech Poverty of thought content	Taciturnity Thought blocking
Cluster 7 (abnormal reasoning-related)	Ideas of reference Illogical thinking	Impaired reasoning Magical thinking	Paralogism
Cluster 8 (stereotypy- related)	Coprolalia Echolalia	Perseveration Repetitive speech	Verbigeration
Cluster 9 (incoherence-related)	Disorganized speech Incoherent Clang associations	Derailment Loose associations Tangentiality	Thinking abnormal
Other terms excluded from clusters	Pedantic speech Intellectualization Morbid thoughts Pathological doubt Intrusive thoughts Circumstantiality	Speech disorder developmental Mutism Speech disorder Cognitive linguistic disorder	Social communication disorder Language disorder Speech sound disorder Slow speech Confabulation





